Orbimed Advisors reduced stake in Oric Pharmaceuticals, Inc. By Investing.com

© Reuters. Orbimed Advisors reduced stake in Oric Pharmaceuticals, Inc.

On the 24th of March, Orbimed Advisors sold 112 thousand Oric Pharmaceuticals, Inc. (ORIC) shares for $2.8 million at an average price of $24.53 per share.
Shares of Oric Pharmaceuticals, Inc. are up 17.58% since the transaction.

Orbimed Advisors’s holding in Oric Pharmaceuticals, Inc. decreased to about 2.3 million shares with the transaction.

Orbimed Advisors first bought Oric Pharmaceuticals, Inc. stock in the second quarter of 2020.
Orbimed Advisors also owns Arcutis Biotherapeutics, Inc. (NASDAQ:), Biogen Inc (NASDAQ:), Eledon Pharmaceuticals, Inc. (ELDN) and Neurocrine Biosciences Inc (NASDAQ:).
Oric Pharmaceuticals, Inc. is its number nineteen position by number of shares and market value among pharmaceuticals stocks.

In contrast, Alkeon Capital Management, California State Teachers Retirement System, and Citigroup (NYSE:) added to ORIC shares.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link